Phosphonoformate Crystalluria, A Warning Signal of Foscarnet-Induced Kidney Injury

Christine Deffert1,2, Catherine Stoermann3, Thomas Ernandez3, Mitja Nabergoj4, Yves Chalandon4 and Philippe Jaeger3,5

1Division of Laboratory Medicine, Diagnostic Department, Geneva University Hospitals, Geneva, Switzerland; 2Division of Laboratory Medicine, Department of Medical Specialties, Faculty of Medicine, University of Geneva, Geneva, Switzerland; 3Division of Nephrology, University Hospital and Faculty of Medicine of Geneva, Geneva, Switzerland; 4Division of Haematology, Department of Oncology, University Hospital and Faculty of Medicine of Geneva, Geneva, Switzerland; and 5Center for Nephrology, Royal Free, University College of London, London, UK

Correspondence: Christine Deffert, Division of Laboratory Medicine, Diagnostic Department, Geneva University Hospitals, Gabrielle-Perret-Gentil, 4, 1211 Geneva, Switzerland. E-mail: christine.deffert@hcuge.ch

Received 3 July 2020; revised 11 August 2020; accepted 18 August 2020; published online 22 August 2020

Kidney Int Rep (2020) 5, 2102–2108; https://doi.org/10.1016/j.ekir.2020.08.019
© 2020 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

INTRODUCTION

Foscarnet (pyrophosphate analog trisodium phosphonoformate) is the standard treatment of ganciclovir-resistant cytomegalovirus (CMV) infections or when administration of ganciclovir is not possible. It acts as an inhibitor of DNA polymerase and retroviral reverse transcriptase of all herpes viruses. Adverse effects are numerous and include nephrotoxicity and electrolyte disorders such as hypocalcemia.

Foscarnet has been reported to induce reversible acute kidney injury (AKI), kidney tubular necrosis, distal tubular acidosis, and nephrogenic diabetes insipidus. Reported incidence of foscarnet nephrotoxicity varies between 20% and 66%.

Foscarnet-induced kidney injury has been largely attributed to tubulointerstitial damage, but crystal deposits in tubular cells or tubular lumens as well as in glomerular capillaries have been repeatedly reported, suggesting that a form of crystalline nephropathy may be another causative mechanism. Already in 1990 phosphonoformate crystals were observed within glomerular capillary lumens in kidney biopsy material from patients treated with foscarnet with infrared documentation of the crystals in 1998. Phosphonoformate crystals have been found deposited in various organs, mostly in the kidney, and numerous reports of crystal deposition in kidney biopsy material have been published ever since.

Until now, the relative contribution of phosphonoformate crystal deposition to foscarnet-induced nephrotoxicity has remained uncertain because patients receiving the antiviral drug suffer from severe concurrent pathologies and are often treated with other nephrotoxic drugs. Another reason for said uncertainty is that other drugs potentially leading to crystalline obstruction, such as acyclovir and indinavir, have been associated with presence of crystals in urine, whereas such was not the case for foscarnet.

In this article, we describe for the first time phosphonoformate crystalluria observed in 6 cases treated with foscarnet. Reports of 6 patients treated with foscarnet and whose urinary sediment revealed presence of phosphonoformate crystals in urinary sediments.

CASE PRESENTATION

Clinical and Biological Data

Reports of 6 patients treated with foscarnet and whose urinary sediment revealed presence of phosphonoformate crystals in urinary sediments.

Patient 1

A 71-year-old woman diagnosed with acute myeloid leukemia underwent, while in complete remission, a nonmyeloablative allogeneic hematopoietic stem cell transplantation with HLA-compatible unrelated donor. Conditioning regimen consisted in fludarabine and total body irradiation; graft-versus-host disease (GvHD) prophylaxis consisted of mycophenolate mofetil and ciclosporine. Following transplantation, the patient presented multiple complications such as a reactivation of CMV disease (CMV serostatus: D−, R+). Ganciclovir was administered without effect on the viral load of CMV. Hence, based on in vitro documentation of resistance of
CMV to ganciclovir, the patient was switched to foscar- 
et. Phosphonoformurate crystalluria (proven by infrared spectrometry) was observed 14 days after the onset of foscarnet therapy and associated with a non- 
glomerular hematuria and renal tubular epithelial cells in urine sediment. Progressive elevation of serum 
creatinine concentration occurred (AKI Kidney Disease: 
Improving Global Outcomes [KDIGO] stage 3), despite 
adaptation of foscarnet doses to kidney function. 
The patient died after probable fungal bronchopneumonia 
and septicemia while still on foscarnet.

Patient 2
A 35-year-old man diagnosed with acute lymphoblastic 
leukemia achieved a second complete remission 
following salvage chemotherapy after a first relapse. 
Stem cell transplantation from an HLA-matched unrel- 
ated donor was performed following myeloablative 
conditioning. CMV serostatus was D−, R−. To prevent 
GvHD, cyclosporine with a short course of methotrexate 
as administered. Numerous complications occurred 
after transplantation, including an human herpesvirus 6 
encephalitis. For the latter, ganciclovir was started and 
replaced after 24 hours by foscarnet because of concerns 
about known associated myelotoxicity with high doses 
of ganciclovir. Phosphonoformurate crystalluria (proven 
by infrared spectrometry) was observed 7 days after 
onset of foscarnet associated with a nonglomerular hem- 
turia but without renal tubular epithelial cells in urine sediment. Because of a stable kidney function, 
foscarnet administration was maintained at unchanged 
doses. Despite the human herpesvirus 6 encephalitis 
resolution, the patient died from acute respiratory fail- 
ure due to uncontrolled bleeding.

Patient 3
A 59-year-old woman diagnosed with acute myeloid 
leukemia received successfully an allogeneic hematopoietic stem cell transplantation from an HLA-
compatible unrelated donor following a reduced-intensity conditioning. The GvHD prophylaxis regimen was mycophenolate mofetil and cyclo-
sporine. In the post-transplantation phase, the patient 
presented several complications, such as reactivation of 
CMV disease (CMV serostatus: D+, R+). Foscarnet was 
initiated and phosphonoformurate crystalluria (proven 
by infrared spectrometry) was observed 7 days after 
onset of therapy associated with renal tubular epithelial 
cells in urine sediment. No hematuria was observed. 
The patient developed AKI KDIGO stage 1 24 days after 
foscarnet initiation.

Patient 4
This patient was a 63-year-old man who underwent 
liver transplantation for alcohol-induced cirrhosis. 
Despite anti-CMV (serostatus D+, R−) prophylaxis, the 
patient developed CMV infection against what he first 
received valganciclovir. The viral load of CMV further 
increasing, the patient was switched to foscarnet; 
however, phosphonoformurate crystalluria (proven by 
infrared spectrometry) was observed 1 month after 
onset of the treatment with foscarnet and was accom- 
pained by glomerular haematuria, leukocyturia, and 
renal tubular epithelial cells in urine sediment. The 
patient developed AKI KDIGO stage 1 47 days after 
onset of the treatment with foscarnet. CMV viral load 
decreased but remained present under bitherapy (fos- 
carnet/ganciclovir, then ganciclovir/letermovir). 
Elevated creatinine persisted despite discontinuation of 
foscarnet.

Patient 5
A 73-year-old man, previously diagnosed with myelo-
dysplastic syndrome, underwent hematopoietic stem 
cell transplantation from an HLA-haploidentical donor. 
CMV serostatus: D−, R−. GvHD prophylaxis consisted 
of post-transplant cyclophosphamide, tacrolimus, and 
mycophenolate mofetil. In the post-transplantation phase, the patient presented several complications, 
including oral herpes (HSV1) infection. Because of proven in vitro valaciclovir resistance, foscarnet was 
introduced: phosphonoformurate crystalluria was 
observed at day 11 after onset of therapy. Neither red 
blood cells nor any other cells were seen in the urine 
sediment. The patient developed AKI KDIGO stage 2 at 
day 12. The viral infection was effectively treated, but 
the patient died 2 months later due to an invasive fungal infection.

Patient 6
This patient was a 70-year-old woman, diagnosed with 
high-grade myelodysplastic syndrome. After having 
achieved remission with systemic chemotherapy, she 
underwent a haploidentical stem cell transplantation. 
For GvHD prevention, she received post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil. CMV serostatus: D−, R+. Despite anti-CMV prophylaxis with letermovir, CMV viral load 
increased from month 3 on, and a preemptive treatment 
with valganciclovir was introduced. Given a further 
increment of the viral load despite this treatment,
foscarnet was subsequently started. Phosphonoformate crystalluria (proven by infrared spectrometry) was observed at day 9 after onset of foscarnet associated with a nonglomerular hematuria and renal tubular epithelial cells in urine sediment. The patient developed AKI KDIGO stage 1 at day 14.

Figure 1. Foscarnet crystals in urinary sediment. Phosphonoformate crystals visualized by contrast phase microscopy (a) and polarized light with compensatory lens (b). Original magnification ×400.

Case 1

Case 2

Case 3

Case 4

Case 6
Figure 2. Infrared (IR) spectra of the crystals found in urine of 4 patients. IR analysis was performed in urine from 4 cases (patients 1, 3, 4, and 6). Four IR spectra of urinary crystals from each patient had typical IR bands of foscarinet: 1540 and 1395 cm\(^{-1}\) (carboxylate domain) and 1169, 1119, and 1082 cm\(^{-1}\) (phosphate domain). Spectra included 2 more bands at 971 and 991 cm\(^{-1}\). P, patient.
Crystalluria
Phosphonoformate crystals exhibited rectangular and square shapes, sometimes shapes of a thin stick when they were positioned on the edge. They often formed large aggregates. Their sizes varied from 16 to 70 μm (Figure 1). Single crystals did not polarize; they only did so when present as aggregates. The number of crystals varied greatly from patient to patient and even between samples from the same patient. pH of urine containing crystals ranged from 5.5 to 7.5.

Urinary Crystal Identification
All analyzed Fourier-transform infrared (FTIR) spectra of urinary crystals had typical infrared (IR) bands of foscarnet: 1540 and 1395 cm\(^{-1}\) (carboxylate domain) and 1169, 1119, and 1082 cm\(^{-1}\) (phosphate domain) (Figure 2). These FTIR measurements confirmed that the crystals observed in those urine sediments were made of phosphonoformate.

The 4 urine specimens analyzed by IR spectrometry displayed differences in intensity between bands 971 and 991 cm\(^{-1}\). The band at 991 cm\(^{-1}\) was higher than that at 971 cm\(^{-1}\) in patients 1 and 4, but for patients 3 and 6, band intensity at 971 and 991 were equal. Thus, the proportion of both salts in the mix varied from one patient to another.

Acute Kidney Injury
Among the 6 patients treated with foscarnet and who presented with phosphonoformate crystalluria, 5 of them further developed a kidney injury (Figure 3). Patient 1 developed AKI KDIGO stage 3; patient 5 stage 2; and patients 3, 4, and 6 stage 1. After onset of foscarnet therapy, the median time lag for phosphonoformate crystalluria to appear was 11 days (range 7 to 27 days), whereas that for AKI to occur was 24 days (range 12 to 47 days). Occurrence of AKI always followed appearance of crystalluria by a median time lag of 11 days. Patients with crystalluria presented diluted urine as estimated by specific gravity ranging from 1.004 to 1.014. Among the 5 patients with AKI, 4 of them showed in their urine sediment crystalluria and leukocyturia and/or renal tubular epithelial cells. None of them showed casts.

As serum creatinine level increased, the amount of crystals in urine decreased (median serum creatinine was 112.5 μmol/l when crystal quantities were
estimated at +, median serum creatinine was 86 μmol/l when crystal quantities were estimated at ++, and finally median serum creatinine was 77 μmol/l when crystal quantities were estimated at +++). The semi-quantitative determination of crystals was defined as: +, 1 per 3 high-power fields; ++, 2–4 per high-power fields; and ++++, more than 4 per high-power fields defined in Supplementary Methods.

The higher the dose of foscarnet administered, the earlier phosphonoformate crystalluria appeared. The 3 patients (patients 2, 3, and 6) who received doses of more than 10 g per day were also those who had the earliest crystalluria, that is, fewer than 10 days after the onset of treatment. On the other hand, the early onset of AKI was not related to high doses of foscarnet (Figure 3).

Reduction of foscarnet doses was not associated with any decline in serum creatinine concentrations. Only withdrawal of treatment after short-term treatment (<20 days) allowed reversibility of kidney impairment (patients 3, 5, and 6).

DISCUSSION

We report the first identification of phosphonoformate crystals in urine of patients treated with foscarnet, and describe the time lag between appearance of crystalluria and AKI known to occur in the context of that therapy.

Phosphonoformate crystals in material obtained from kidney biopsies have been described as “short polarized sticks with angular edges.”1,2 Urine crystals had a similar shape but did not polarize as single crystals, whereas they did so when aggregated in clusters as it occurs in the kidney issue. Because phosphonoformate crystals had never been reported in urine before, identification by IR spectroscopy in urine sediments was required to confirm their chemical composition. We found the typical bands previously reported,2,3,51 confirming that the observed crystals were indeed made of phosphonoformate.

Phosphonoformate may crystallize as calcium salt or as sodium salt.2,3 Based on in vitro experiments, calcium salt is less soluble in urine than sodium salt of phosphonoformic acid. In this report, we have found a mix of sodium and calcium salts of phosphonoformic acid crystallized in urine. On the other hand, we have not found crystals corresponding to trisodium phosphonoformate. Patients 3 and 6 displayed an equal proportion of sodium and of calcium salts, as opposed to the other 2 patients (1 and 4) for which IR band intensity of calcium salts (991 cm⁻¹) were dominant compared with those of sodium salts (971 cm⁻¹). Patients 3 and 6 were also patients with few episodes of crystalluria and who only developed AKI stage 1 as opposed to other patients (stage 3 and 2, respectively, for patient 1 and 4). An equal proportion of sodium and calcium salts might have attenuated the trend for phosphonoformic acid to crystallize, and thereby the potential severity of kidney injury. If this were true, the spectrum of the crystals and the salt proportion of both salts at IR of urine sediments might turn out to help and predict the degree of severity of kidney damage.

Numerous risk factors of drug crystallization have been recognized so far2,5: they may be related to the drug (dose, duration of treatment, solubility, simultaneous use of other molecules) or related to the patient (urinary pH, urine specific gravity, or stasis).4 Overall, we have not identified risk factors for foscarnet crystallization in urine (Figure 3). Patients reported to have developed AKI after foscarnet infusion classically received repeated and/or high doses of the drug (i.e., 6 to 12 g per day).4 Our patients who developed crystalluria had received foscarnet doses ranging from 3 to 14 g per day; however, severity of crystalluria or of AKI did not appear to be related to the actual dose of foscarnet given. On the other hand, the 3 patients who developed a rapid onset of phosphonoformate crystalluria (7 and 9 days) had received daily doses of more than 10 g.

Duration of treatment seems to have an effect on the reversibility of the kidney damage. Indeed, the 3 patients (3, 5, and 6) with the shortest treatment time presented a rapidly reversible AKI.

Infusion of large volumes of isotonic saline, 1.5 to 2.5 liters per day, has been demonstrated to reduce kidney toxicity of foscarnet by decreasing the urinary concentration of the drug.4–6 Nevertheless, despite an appropriate hydration as illustrated by their very low urine specific gravity, patients presented phosphonoformate crystals in their urine. In urine with phosphonoformate crystals, the spectrum of pH ranged from 5.5 to 7.5 (data not shown). Crystallization of foscarnet does not seem to depend on urine pH, and alkalization of urine is probably of no help for crystal solubilization. The occurrence of foscarnet crystallization did not show differences between acidic or alkaline urine. Finally, foscarnet nephrotoxicity might be amplified by concurrent administration of other nephrotoxic drugs. In our report, one patient simultaneously received cyclosporine and foscarnet (patient 2) but he was also the only one whose serum creatinine concentration remained stable.

Presence of crystalluria is a sign of supersaturation of urine and does not necessarily imply that associated-AKI is due to crystalline nephropathy. In absence of
kidney biopsy, only crystalline casts in urine sediment would suggest such a causal link. Unfortunately, crystalline casts are rarely found in urine. On the other hand, white blood cells, renal tubular epithelial cells, or casts in sediment-associated crystalluria indicate also intrarenal crystal-related injury. In analyzed urine sediment, 4 patients showed white blood cells or renal tubular cells enhancing the fact that crystalluria might cause kidney injury. The patient who did not develop AKI did not have white blood cells or renal tubular epithelial cells in urine sediment.

Presence of foscarnet (phosphonoformate) crystals in urine may be a predictive factor of crystalline nephropathy. However, 5 of the 6 cases received allogeneic hematopoietic stem cell transplantation and presented with variable degrees of thrombocytopenia preventing kidney biopsy to determine the underlying cause of AKI. The discovery of phosphonoformate crystals in urine allows, in these cases, to strongly suspect foscarnet nephrotoxicity without invasive procedure.

This observation raises new questions, such as the following.

- Why is it the first time that phosphonoformate crystalluria is described in patients on foscarnet therapy, whereas phosphonoformate crystals have been known for years to be deposited in various organs of patients treated with that drug? Maybe early check for crystals in urine has never been considered before; or maybe at the time kidney injury occurs tubular obstruction prevents further release of crystals in urine. We have presented some evidence to support this latter hypothesis: crystalluria always appeared ahead of kidney injury onset; the median time lag for phosphonoformate crystalluria to appear was 11 days, whereas that for AKI to occur was 24 days. Occurrence of AKI always followed appearance of crystalluria by a median time lag of 11 days. On the other hand, serum creatinine level increased when the amount of crystals in urine decreased.

- Where do the crystals actually first form? Is it in the glomerular urinary space or in a specific segment of the kidney tubules? This would need to be reconciled with previous observations of phosphonoformate crystal deposition in the lumen of glomerular capillaries.

**CONCLUSIONS**

The present report highlights the fact that phosphonoformate crystals in urine of patients treated with foscarnet may be taken as a warning signal of imminent development of AKI induced by the drug. This should trigger preemptive measures, such as hyperhydration, dose down titration, or consideration of an alternative regimen, although conclusive evidence of the effectiveness of those actions is lacking.

**DISCLOSURE**

All the authors declared no competing interests.

**ACKNOWLEDGEMENTS**

PJ is the recipient of a grant from the Association Enfance & Maladies Orphelines to which he wishes to express his gratitude for the generous support.

**SUPPLEMENTARY MATERIAL**

Supplementary File (PDF)
Supplementary Methods.
Supplementary References.

**REFERENCES**

1. Izzedine H, Launay-Vacher V, Deray G. Antiviral drug-induced nephrotoxicity. Am J Kidney Dis. 2005;45:804–817.
2. Deray G, Martinez F, Katlama C, et al. Foscarnet nephrotoxicity: mechanism, incidence and prevention. Am J Nephrol. 1989;9:316–321.
3. Maurice-Estepa L, Daudon M, Katlama C, et al. Identification of crystals in kidneys of AIDS patients treated with foscarnet. Am J Kidney Dis. 1998;32:392–400.
4. Jacobson MA. Review of the toxicities of foscarnet. J Acquir Immune Defic Syndr (1988). 1992;5(Suppl 1):S11–S17.
5. Justrabo E, Zanetta G, Martin L, et al. Irreversible glomerular lesions induced by crystal precipitation in a renal transplant after foscarnet therapy for cytomegalovirus infection. Histopathology. 1999;34:365–369.
6. Beaufils H, Deray G, Katlama C, et al. Foscarnet and crystals in glomerular capillary lumens. Lancet. 1990;336:755.
7. Tischler V, Schuurmans MM, Boehler A, et al. Crystal precipitation and granulomatous inflammation in multiple organs after foscarnet therapy in a lung transplant recipient. The J Heart Lung Transplant. 2012;31:1037–1040.
8. Philipponnet C, Michel PA, Daudon M, et al. Intravascular foscarnet crystal precipitation causing multiorgan failure. Am J Kidney Dis. 2015;65:152–155.
9. Goldfarb DS, Coe FL. Foscarnet crystal deposition and renal failure. Am J Kidney Dis. 1998;32:519–520.